Comment diagnostique-t-on un dermatofibrosarcome ?
Le diagnostic repose sur l'examen clinique et une biopsie pour analyse histologique.
BiopsieDermatofibrosarcome
#2
Quels examens complémentaires sont nécessaires ?
Des examens d'imagerie comme l'IRM peuvent être utilisés pour évaluer l'extension tumorale.
Imagerie par résonance magnétiqueDermatofibrosarcome
#3
Quels signes cliniques indiquent un dermatofibrosarcome ?
Une lésion cutanée ferme, indolore, souvent pigmentée, qui évolue lentement.
Lésion cutanéeDermatofibrosarcome
#4
Le dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?
Oui, il peut être confondu avec des lipomes ou d'autres tumeurs cutanées bénignes.
Tumeurs cutanéesDermatofibrosarcome
#5
Quel rôle joue l'histopathologie dans le diagnostic ?
L'histopathologie permet de confirmer la nature maligne de la tumeur et son type histologique.
HistopathologieDermatofibrosarcome
Symptômes
5
#1
Quels sont les symptômes d'un dermatofibrosarcome ?
Les symptômes incluent une masse cutanée indolore, souvent avec des bords bien définis.
SymptômesDermatofibrosarcome
#2
Le dermatofibrosarcome provoque-t-il des douleurs ?
En général, il est indolore, mais des douleurs peuvent survenir si la tumeur est compressive.
DouleurDermatofibrosarcome
#3
Peut-on observer des changements de couleur sur la lésion ?
Oui, la lésion peut présenter des variations de couleur, souvent brunâtre ou violacée.
Changements de couleurDermatofibrosarcome
#4
Les démangeaisons sont-elles fréquentes ?
Les démangeaisons ne sont pas courantes, mais peuvent survenir dans certains cas.
DémangeaisonsDermatofibrosarcome
#5
La lésion peut-elle saigner ?
La lésion peut saigner, surtout si elle est traumatisée ou si elle est en surface.
SaignementDermatofibrosarcome
Prévention
5
#1
Peut-on prévenir le dermatofibrosarcome ?
Il n'existe pas de méthode de prévention spécifique, mais éviter les traumatismes cutanés peut aider.
PréventionDermatofibrosarcome
#2
Les personnes à risque doivent-elles être surveillées ?
Oui, les personnes ayant des antécédents familiaux ou des lésions cutanées doivent être surveillées.
SurveillanceDermatofibrosarcome
#3
L'exposition au soleil influence-t-elle le risque ?
Une exposition excessive au soleil peut augmenter le risque de certains cancers cutanés, mais pas spécifiquement du dermatofibrosarcome.
Exposition au soleilDermatofibrosarcome
#4
Des mesures de protection cutanée sont-elles recommandées ?
Oui, utiliser des écrans solaires et porter des vêtements protecteurs est conseillé.
Protection cutanéeDermatofibrosarcome
#5
Les vaccinations peuvent-elles aider à prévenir le cancer ?
Certaines vaccinations peuvent prévenir des infections liées à des cancers, mais pas spécifiquement le dermatofibrosarcome.
VaccinationDermatofibrosarcome
Traitements
5
#1
Quel est le traitement principal du dermatofibrosarcome ?
Le traitement principal est la chirurgie pour enlever complètement la tumeur.
ChirurgieDermatofibrosarcome
#2
La radiothérapie est-elle utilisée ?
La radiothérapie peut être utilisée en complément après la chirurgie pour réduire le risque de récidive.
RadiothérapieDermatofibrosarcome
#3
Des traitements médicamenteux sont-ils disponibles ?
Des traitements ciblés peuvent être envisagés dans les cas avancés ou récidivants.
Traitements médicamenteuxDermatofibrosarcome
#4
Quelle est l'importance de la surveillance post-opératoire ?
La surveillance est cruciale pour détecter rapidement toute récidive de la tumeur.
Surveillance post-opératoireDermatofibrosarcome
#5
Peut-on traiter le dermatofibrosarcome par chimiothérapie ?
La chimiothérapie n'est généralement pas efficace pour le dermatofibrosarcome, sauf cas avancés.
ChimiothérapieDermatofibrosarcome
Complications
5
#1
Quelles sont les complications possibles du dermatofibrosarcome ?
Les complications incluent la récidive locale et, dans de rares cas, des métastases.
ComplicationsDermatofibrosarcome
#2
Le dermatofibrosarcome peut-il se propager ?
Il a un faible potentiel de métastase, mais peut envahir les tissus voisins.
MétastasesDermatofibrosarcome
#3
Comment gérer une récidive de dermatofibrosarcome ?
La récidive nécessite souvent une nouvelle intervention chirurgicale et un suivi étroit.
RécidiveDermatofibrosarcome
#4
Les cicatrices peuvent-elles poser problème après traitement ?
Oui, les cicatrices peuvent être inesthétiques et nécessiter des soins ou des interventions esthétiques.
CicatricesDermatofibrosarcome
#5
Y a-t-il des risques psychologiques associés ?
Oui, le diagnostic et le traitement peuvent entraîner du stress et de l'anxiété chez les patients.
Santé mentaleDermatofibrosarcome
Facteurs de risque
5
#1
Quels sont les facteurs de risque du dermatofibrosarcome ?
Les facteurs incluent des antécédents de traumatismes cutanés, des maladies génétiques et l'exposition à des radiations.
Facteurs de risqueDermatofibrosarcome
#2
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de dermatofibrosarcome peuvent augmenter le risque.
Antécédents familiauxDermatofibrosarcome
#3
L'âge influence-t-il le risque de dermatofibrosarcome ?
Le dermatofibrosarcome est plus fréquent chez les adultes jeunes, généralement entre 20 et 50 ans.
ÂgeDermatofibrosarcome
#4
Les infections virales sont-elles un facteur de risque ?
Certaines infections virales, comme le virus de l'herpès, peuvent être associées à un risque accru.
Infections viralesDermatofibrosarcome
#5
Le sexe influence-t-il le risque de dermatofibrosarcome ?
Il n'y a pas de différence significative entre les sexes concernant le risque de dermatofibrosarcome.
SexeDermatofibrosarcome
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dermatofibrosarcome : Questions médicales les plus fréquentes",
"headline": "Dermatofibrosarcome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dermatofibrosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-05",
"dateModified": "2025-03-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dermatofibrosarcome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Fibrosarcome",
"url": "https://questionsmedicales.fr/mesh/D005354",
"about": {
"@type": "MedicalCondition",
"name": "Fibrosarcome",
"code": {
"@type": "MedicalCode",
"code": "D005354",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.795.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dermatofibrosarcome",
"alternateName": "Dermatofibrosarcoma",
"code": {
"@type": "MedicalCode",
"code": "D018223",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Aseel Sleiwah",
"url": "https://questionsmedicales.fr/author/Aseel%20Sleiwah",
"affiliation": {
"@type": "Organization",
"name": "Department of Plastic and Reconstructive Surgery, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK. aseelnajeeb@yahoo.com."
}
},
{
"@type": "Person",
"name": "Yoshinao Oda",
"url": "https://questionsmedicales.fr/author/Yoshinao%20Oda",
"affiliation": {
"@type": "Organization",
"name": "Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. oda.yoshinao.389@m.kyushu-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Katherine E Mallett",
"url": "https://questionsmedicales.fr/author/Katherine%20E%20Mallett",
"affiliation": {
"@type": "Organization",
"name": "Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A."
}
},
{
"@type": "Person",
"name": "Ryan M Claxton",
"url": "https://questionsmedicales.fr/author/Ryan%20M%20Claxton",
"affiliation": {
"@type": "Organization",
"name": "Alix School of Medicine, Mayo Clinic, Rochester, MN, U.S.A."
}
},
{
"@type": "Person",
"name": "Peter C Ferguson",
"url": "https://questionsmedicales.fr/author/Peter%20C%20Ferguson",
"affiliation": {
"@type": "Organization",
"name": "Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Redefining Health Care Data Interoperability: Empirical Exploration of Large Language Models in Information Exchange.",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38819879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/56614"
}
},
{
"@type": "ScholarlyArticle",
"name": "Building consensus on common features and interoperability use cases for community health information systems: a Delphi study.",
"datePublished": "2024-04-24",
"url": "https://questionsmedicales.fr/article/38663904",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjgh-2023-014001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Towards an Interoperability Landscape for a National Research Data Infrastructure for Personal Health Data.",
"datePublished": "2024-07-13",
"url": "https://questionsmedicales.fr/article/39003329",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41597-024-03615-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Making Science Computable Using Evidence-Based Medicine on Fast Healthcare Interoperability Resources: Standards Development Project.",
"datePublished": "2024-06-25",
"url": "https://questionsmedicales.fr/article/38916936",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/54265"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Evolution of Health Information Technology for Enhanced Patient-Centric Care in the United States: Data-Driven Descriptive Study.",
"datePublished": "2024-10-28",
"url": "https://questionsmedicales.fr/article/39466303",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/59791"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sarcomes",
"item": "https://questionsmedicales.fr/mesh/D012509"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fibrosarcome",
"item": "https://questionsmedicales.fr/mesh/D005354"
},
{
"@type": "ListItem",
"position": 7,
"name": "Dermatofibrosarcome",
"item": "https://questionsmedicales.fr/mesh/D018223"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dermatofibrosarcome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dermatofibrosarcome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dermatofibrosarcome",
"description": "Comment diagnostique-t-on un dermatofibrosarcome ?\nQuels examens complémentaires sont nécessaires ?\nQuels signes cliniques indiquent un dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?\nQuel rôle joue l'histopathologie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dermatofibrosarcome",
"description": "Quels sont les symptômes d'un dermatofibrosarcome ?\nLe dermatofibrosarcome provoque-t-il des douleurs ?\nPeut-on observer des changements de couleur sur la lésion ?\nLes démangeaisons sont-elles fréquentes ?\nLa lésion peut-elle saigner ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dermatofibrosarcome",
"description": "Peut-on prévenir le dermatofibrosarcome ?\nLes personnes à risque doivent-elles être surveillées ?\nL'exposition au soleil influence-t-elle le risque ?\nDes mesures de protection cutanée sont-elles recommandées ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dermatofibrosarcome",
"description": "Quel est le traitement principal du dermatofibrosarcome ?\nLa radiothérapie est-elle utilisée ?\nDes traitements médicamenteux sont-ils disponibles ?\nQuelle est l'importance de la surveillance post-opératoire ?\nPeut-on traiter le dermatofibrosarcome par chimiothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dermatofibrosarcome",
"description": "Quelles sont les complications possibles du dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il se propager ?\nComment gérer une récidive de dermatofibrosarcome ?\nLes cicatrices peuvent-elles poser problème après traitement ?\nY a-t-il des risques psychologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dermatofibrosarcome",
"description": "Quels sont les facteurs de risque du dermatofibrosarcome ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge influence-t-il le risque de dermatofibrosarcome ?\nLes infections virales sont-elles un facteur de risque ?\nLe sexe influence-t-il le risque de dermatofibrosarcome ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Health+Information+Interoperability#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un dermatofibrosarcome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et une biopsie pour analyse histologique."
}
},
{
"@type": "Question",
"name": "Quels examens complémentaires sont nécessaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme l'IRM peuvent être utilisés pour évaluer l'extension tumorale."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un dermatofibrosarcome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une lésion cutanée ferme, indolore, souvent pigmentée, qui évolue lentement."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec des lipomes ou d'autres tumeurs cutanées bénignes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'histopathologie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'histopathologie permet de confirmer la nature maligne de la tumeur et son type histologique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un dermatofibrosarcome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une masse cutanée indolore, souvent avec des bords bien définis."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome provoque-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "En général, il est indolore, mais des douleurs peuvent survenir si la tumeur est compressive."
}
},
{
"@type": "Question",
"name": "Peut-on observer des changements de couleur sur la lésion ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la lésion peut présenter des variations de couleur, souvent brunâtre ou violacée."
}
},
{
"@type": "Question",
"name": "Les démangeaisons sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les démangeaisons ne sont pas courantes, mais peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "La lésion peut-elle saigner ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La lésion peut saigner, surtout si elle est traumatisée ou si elle est en surface."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le dermatofibrosarcome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais éviter les traumatismes cutanés peut aider."
}
},
{
"@type": "Question",
"name": "Les personnes à risque doivent-elles être surveillées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant des antécédents familiaux ou des lésions cutanées doivent être surveillées."
}
},
{
"@type": "Question",
"name": "L'exposition au soleil influence-t-elle le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive au soleil peut augmenter le risque de certains cancers cutanés, mais pas spécifiquement du dermatofibrosarcome."
}
},
{
"@type": "Question",
"name": "Des mesures de protection cutanée sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, utiliser des écrans solaires et porter des vêtements protecteurs est conseillé."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections liées à des cancers, mais pas spécifiquement le dermatofibrosarcome."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du dermatofibrosarcome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la chirurgie pour enlever complètement la tumeur."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut être utilisée en complément après la chirurgie pour réduire le risque de récidive."
}
},
{
"@type": "Question",
"name": "Des traitements médicamenteux sont-ils disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés peuvent être envisagés dans les cas avancés ou récidivants."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance post-opératoire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter rapidement toute récidive de la tumeur."
}
},
{
"@type": "Question",
"name": "Peut-on traiter le dermatofibrosarcome par chimiothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie n'est généralement pas efficace pour le dermatofibrosarcome, sauf cas avancés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du dermatofibrosarcome ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la récidive locale et, dans de rares cas, des métastases."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome peut-il se propager ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il a un faible potentiel de métastase, mais peut envahir les tissus voisins."
}
},
{
"@type": "Question",
"name": "Comment gérer une récidive de dermatofibrosarcome ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La récidive nécessite souvent une nouvelle intervention chirurgicale et un suivi étroit."
}
},
{
"@type": "Question",
"name": "Les cicatrices peuvent-elles poser problème après traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cicatrices peuvent être inesthétiques et nécessiter des soins ou des interventions esthétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques psychologiques associés ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic et le traitement peuvent entraîner du stress et de l'anxiété chez les patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du dermatofibrosarcome ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de traumatismes cutanés, des maladies génétiques et l'exposition à des radiations."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dermatofibrosarcome peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dermatofibrosarcome ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dermatofibrosarcome est plus fréquent chez les adultes jeunes, généralement entre 20 et 50 ans."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus de l'herpès, peuvent être associées à un risque accru."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de dermatofibrosarcome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de différence significative entre les sexes concernant le risque de dermatofibrosarcome."
}
}
]
}
]
}
Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. oda.yoshinao.389@m.kyushu-u.ac.jp.
Efficient data exchange and health care interoperability are impeded by medical records often being in nonstandardized or unstructured natural language format. Advanced language models, such as large ...
This study aims to evaluate the capability of LLMs in transforming and transferring health care data to support interoperability....
Using data from the Medical Information Mart for Intensive Care III and UK Biobank, the study conducted 3 experiments. Experiment 1 assessed the accuracy of transforming structured laboratory results ...
The text-based approach showed a high conversion accuracy in transforming laboratory results (experiment 1) and an enhanced consistency in diagnostic code conversion, particularly for frequently used ...
This study highlighted the potential role of LLMs in significantly improving health care data interoperability, demonstrated by their high accuracy and efficiency in data transformation and exchange. ...
Information systems for community health have become increasingly sophisticated and evidence-based in the last decade and they are now the most widely used health information systems in many low-incom...
A Delphi study was conducted among a systematically selected panel of CHIS experts. This impressive pool of experts represented a range of leading global health institutions, with gender and regional ...
CHISs today are expected to adapt to a wide range of local contextual requirements and to support and improve care delivery. While once associated with a single role type (CHWs), these systems are now...
CHISs today are expected to be feature-rich, to support a range of user roles in community health systems, and to be highly adaptable to local contextual requirements. Future interoperability efforts,...
The German initiative "National Research Data Infrastructure for Personal Health Data" (NFDI4Health) focuses on research data management in health research. It aims to foster and develop harmonized in...
Evidence-based medicine (EBM) has the potential to improve health outcomes, but EBM has not been widely integrated into the systems used for research or clinical decision-making. There has not been a ...
This study aimed to introduce the EBM on Fast Healthcare Interoperability Resources (FHIR) project (EBMonFHIR), which is extending the methods and infrastructure of Health Level Seven (HL7) FHIR to pr...
As an ongoing process, the project creates and refines FHIR resources to represent evidence from clinical studies and syntheses of those studies and develops tools to assist with the creation and visu...
The EBMonFHIR project created FHIR resources (ie, ArtifactAssessment, Citation, Evidence, EvidenceReport, and EvidenceVariable) for representing evidence. The COVID-19 Knowledge Accelerator (COKA) pro...
EBMonFHIR resources in conjunction with other FHIR resources can support relaying EBM components in a manner that is interoperable and consumable by downstream tools and health information technology ...
Health information technology (health IT) has revolutionized health care in the United States through interoperable clinical care data exchange, e-prescribing, electronic public health reporting, and ...
This study aims to examine progress in health IT adoption and its alignment with the Office of the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health IT (ASTP's) m...
This study leverages data on end users of health IT to capture trends in engagement in interoperable clinical care data exchange (ability to find, send, receive, and integrate information from outside...
Since 2009, there has been a 10-fold increase in electronic health record (EHR) use among hospitals and a 5-fold increase among physicians. This enabled the interoperable exchange of electronic health...
Federal incentives have contributed to the widespread adoption of EHRs and broad digitization in health care, while efforts to promote interoperability have encouraged collaboration across health care...
Reaching meaningful interoperability between proprietary health care systems is a ubiquitous task in medical informatics, where communication servers are traditionally used for referring and transform...
In this study, a generic approach is developed, which allows for the application of declarative mapping rules defined using FML in an exchangeable manner. A transformation engine is required to execut...
FHIR natively defines resources to support the conversion of instance data, such as an FHIR StructureMap. This resource encodes all information required to transform data from a source system to a tar...
The resulting tool is called FML2Mirth, a Java-based transformer that derives Mirth channels from detailed declarative mapping rules based on the underlying StructureMaps. Implementation of the transl...
The tool for the auto-generation of Mirth channels was successfully presented. Our tests reveal the feasibility of using the complex structures of the mapping language in combination with a terminolog...
The lack of interoperability between health information systems reduces the quality of care provided to patients and wastes resources. Accordingly, there is an urgent need to develop integration mecha...
In accordance with the PRISMA guideline, a broad electronic search of all literature was conducted on the topic through six databases, including PubMed, Web of science, Scopus, MEDLINE, Cochrane Libra...
Interoperability has been raised in the field of health information systems from 2003 and now it is one of the topics of interest to researchers. The projects done in this field are mostly in the nati...
The health industry has become more complex and has new needs. Interoperability meets this needs by communicating between the output and input of processor systems and making easier to access the data...
Enabling widespread interoperability-the ability of health information technology systems to exchange information and to use that information without special effort-is a primary focus of public policy...
To assess primary care physician perspectives on the state of interoperability....
A cross-sectional survey of family medicine physicians in the US was conducted from December 12, 2021, to October 12, 2022. A sample of family medicine physicians who completed the Continuous Certific...
Eighteen items on the CCQ assessed experience accessing and using various information from outside organizations, including medications, immunizations, and allergies....
A total of 2088 physicians (1053 women [50%]; age reported categorically as either ≥50 years or <50 years) completed the CCQ interoperability questions in 2022. Of these respondents, 35% practiced in ...
This survey study of family medicine physicians found modest and uneven improvement in physicians' experience with interoperability. These findings suggest that substantial heterogeneity in satisfacti...
To review recent literature on health information exchange (HIE), focusing on the policy approach of five case study nations: the United States of America, the United Kingdom, Germany, Israel, and Por...
A narrative review of each nation's HIE policy frameworks, current state, and future HIE strategy....
Key themes that emerged include the importance of both central decision-making as well as local innovation, the multiple and complex challenges of broad HIE adoption, and the varying role of HIE acros...
HIE is an increasingly important capability and policy priority as electronic health record (EHR) adoption becomes more common and care delivery is increasingly digitized. While all five case study na...
High levels of seamless, bidirectional health information exchange continue to be broadly limited among provider groups despite the vast array of benefits that interoperability entails for patient car...
We aimed to examine the correlation at the provider group level between the distinct directions of interoperability with regard to sending health information and receiving health information, to descr...
We used data from the Centers for Medicare & Medicaid Services (CMS), which included interoperability performance information for 2033 provider groups within the Quality Payment Program Merit-based In...
We found that the examined directions of interoperability-sending health information and receiving health information-have relatively low bivariate correlation (0.4147) with a significant number of ob...
The adoption of interoperability by provider groups is more nuanced than traditionally considered and should not be seen as a binary determination (ie, to be interoperable or not). Asymmetric interope...
